
Participation in the EVA 2023 congress, the University of Patras
Keeping with our continuous goal in attending international congresses associated with an excellent reputation, Rontis had the pleasure of participating as a sponsor in the 3rd EndoVascular Access (EVA) meeting, organised in the Conference & Cultural Centre, the University of Patras, on the 23rd and the 24th of June 2023.
Our team had the privilege to join the congress with a booth and follow a very interesting and educationally rich scientific program that presented the newest updates in the field of peripheral vascular access, through the presentations delivered by the members of the Faculty, comprised by leading experts who visited from a number of countries in the EU and the USA. Moreover, the Meeting attracted a wide audience from the medical, academic, research and industrial/manufacturing sectors, whose contribution was also important to the success of this event.
Beyond our active presence and the opportunity to engage in fruitful formal and informal discussions with the academic Faculty and industrial visitors, joining EVA was of particular importance to Rontis, as we maintain a close collaboration with the scientific committee in the scope of the R&D activities of the Medical Devices division. In fact, as a testament to the successful progress attained by the R&D staff and the company as a whole, Rontis presented the successful results obtained from the pre-clinical testing stage for our novel Everolimus-coated peripheral balloon catheter during the dedicated satellite company symposium. Thus, the goal set upon completion of the previous EVA meeting was achieved and the interest expressed by the leading KOLs in the field reflected the importance of our novel products currently under development in the global market of endovascular medical devices.
We look forward to returning to EVA 2024 and present further successful progress in our R&D and commercial projects, establishing Rontis’ reputation as a manufacturer of innovative and leading quality endovascular devices.
